[肝胆速递] 恩替对乙肝病毒和肝癌抑制作用

bigben446

恩替对乙肝病毒和肝癌抑制作用
Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma

[肝胆速递]：恩替抑制乙肝病毒，对乙肝病毒相关肝癌有改善作用。

[url=http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2011.06776.x/abstract]

Young-Joo Jin M.D. 。。。
DOI: 10.1111/j.1440-1746.2011.06776.x© 2011 Journal of Gastroenterology and Hepatology

Abstract
Background/Aim:
We investigated the efficacy and effectiveness of entecavir in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients.

Methods:
We enrolled 231 nucleoside-naïve chronic hepatitis B (CHB) patients primarily treated with entecavir 0.5 mg/day for at least 6 months in our institution. Of these, 71 patients had HCC at the start of entecavir treatment (HCC group) and 160 did not (non-HCC group). We compared antiviral responses to entecavir in the two groups, and evaluated the effects of entecavir on the clinical outcomes of curatively-treated HCC patients.

Results:
The HCC and non-HCC groups had similar cumulative rates of HBV-DNA negativity, ALT normalization, and hepatitis e antigen loss in year 2 (100% vs. 95.4%, 94.7% vs. 97.3%, and 40.8% vs. 41.8%, respectively; P > 0.05). Entecavir treatment for 12 months decreased mean Model for End-Stage Liver Disease scores in patients with cirrhosis and HCC (7.2 vs. 5.6, P < 0.001). Of the 71 HCC patients, 16 underwent curative therapies concurrently with entecavir; hepatectomy in six and radiofrequency ablation in ten, and the 55 remaining patients received transarterial chemoembolization or conservative treatment. In a subgroup of 16 HCC patients receiving curative treatments, patients who became serum HBV DNA negative by week 24 had better overall survival (P= 0.039), but not recurrence-free survival (P= 0.961), than those who did not.

Conclusions:
First-line entecavir monotherapy is comparably effective in CHB patients with and without HCC, and improves hepatic function in HBV-related HCC patients. An early virological response to entecavir is prognostic of improved survival following curative therapy against HBV-related HCC.







(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

cdw1985

能翻译过来在贴上不？ 要不你就去外国做斑竹吧     我回帖汉字  希望你能看的懂

StephenW

回复 cdw1985 的帖子
注意: 谷歌翻译[不是100％准确]

摘要
背景/目的：
我们调查了乙肝病毒疗效与恩替卡韦的有效性（HBV）的相关肝细胞癌（HCC）患者。

方法：
我们招收231核苷初治慢性乙型肝炎（CHB）患者主要与恩替卡韦0.5 mg /天治疗至少6个月，在我们的机构。其中，71名曾在恩替卡韦治疗（肝癌组）开始肝癌和160没有（非肝癌组）。我们比较恩替卡韦抗病毒反应，在两个组，并评估对治疗性治疗的肝癌患者的临床结局的恩替卡韦的影响。

结果：
肝癌与非肝癌组已对乙肝病毒DNA阴转，ALT复常率相似的累积，和戊型肝炎在第2年（100％比95.4％，94.7％比97.3％，41.8％和40.8％抗原主场迎战损失，均P>0.05）。恩替卡韦治疗12个月降低平均终末期肝病，肝硬化和肝癌（7.2对比5.6，磷“0.001）患者评分模型。在71个肝癌病人，16例疗效与恩替卡韦治疗的同时，在六中肝切除术和射频消融治疗十，其余55位病人接受化学栓塞或保守治疗。在16位接受治疗肝癌的治疗，患者谁成为24周亚组血清HBV DNA转阴有较好的整体存活率（P=0.039），但不无复发存活率（P=0.961）比那些谁没有。

结论：
第一线相对比较单一恩替卡韦与慢性乙型肝炎患者和无肝癌有效，并且提高了HBV相关肝癌患者肝功能。早期病毒学应答对恩替卡韦是改善生存预后以下对HBV相关肝癌根治性治疗。

legendliu

不太懂，呵呵

StephenW

legendliu 发表于 2011-5-28 14:00
不太懂，呵呵

[肝胆速递]：恩替抑制乙肝病毒，对乙肝病毒相关肝癌有改善作用。

买平安的

StephenW 发表于 2011-5-28 14:09
[肝胆速递]：恩替抑制乙肝病毒，对乙肝病毒相关肝癌有改善作用。

复制黏贴党。
百度加google。
没有意见和诊断。
什么意思自己猜。

StephenW

买平安的 发表于 2011-5-28 21:37
复制黏贴党。
百度加google。
没有诊断书。

谢谢, 非常正确, 我不是医生, 不能诊断,不能帮人治病。